A consortium consisting of WhiteOak Capital, Creador, and Siguler Guff has acquired approximately 10% of La Renon Healthcare, valuing the Indian pharmaceutical company at INR 110 billion (~USD 1.2 billion).
Information on the Target
La Renon Healthcare is a prominent pharmaceutical company based in India, focusing on innovation and development of high-quality healthcare products. The company specializes in areas such as the development of prescription medications and over-the-counter products, catering to diverse healthcare needs.
With a growing portfolio of products, La Renon has established itself as a key player in the competitive pharmaceutical landscape in India. Its commitment to research and development, along with a strong distribution network, positions the company for significant growth in both domestic and international markets.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in India
The pharmaceutical industry in India has been experiencing robust growth due to increasing healthcare needs and rising investments in the sector. India is o
Similar Deals
BC Investment (Bain Capital) → Emcure Pharmaceuticals Limited
2025
Somerset → Cyrix Healthcare
2024
ADV Partners → Dr. Agarwal’s Healthcare Limited
Kedaara Capital → Vijaya Diagnostic Centre Private Limited
Quadria Capital → Maxivision Eye Hospital
WhiteOak Capital, Creador, Siguler Guff
invested in
La Renon Healthcare
in
in a Other Private Equity deal
Disclosed details
Transaction Size: $1,200M
Enterprise Value: $1,200M